Company profile: Tissium
1.1 - Company Overview
Company description
- Provider of synthetic, biodegradable, light-activated sealants, surgical adhesives, and biomaterial solutions for wound closure and tissue reconstruction, with a focus on minimally invasive surgery. Offerings include SETALIUM Vascular Sealant, ECLIPSIUM laparoscopic hernia repair system, biomorphic programmable polymers, IBD fistula-healing solutions, and COAPTIUM Connect for sutureless nerve repair.
Products and services
- Biomorphic Programmable Polymers: Fully synthetic polymers developed for tissue reconstruction, adaptable for use in sealants, adhesives, and implantable devices across various clinical areas
- SETALIUM™ Vascular Sealant: Light-activated sealant engineered for vascular reconstruction, producing immediate hemostasis at the surgical site using a synthetic, biodegradable adhesive chemistry
- ECLIPSIUM System: Biodegradable light-activated surgical adhesive system for laparoscopic ventral hernia repair, aiming to reduce tissue trauma during minimally-invasive surgery.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tissium
Esperion Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical products for cardiovascular and metabolic diseases, including bempedoic acid to lower LDL-cholesterol in hypercholesterolemia patients inadequately treated with current lipid-modifying therapies, and a fixed-dose combination of bempedoic acid and ezetimibe to further reduce LDL-cholesterol.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Esperion Therapeutics company profile →
FlowMedica
HQ: United States
Website
- Description: Provider of intravascular systems for implementing targeted renal therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowMedica company profile →
Corvidia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage research, development, and commercialization of transformative therapies for cardio-renal diseases, currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corvidia Therapeutics company profile →
Preventice Solutions
HQ: United States
Website
- Description: Provider of mobile cardiac health solutions and remote monitoring services, connecting patients, clinicians, and hospitals. Offerings include BodyGuardian wearable waterproof ECG monitors and BodyGuardian MINI PLUS for mobile cardiac telemetry; the HIPAA-compliant PatientCare platform for near-real-time data management; and service models from full-service monitoring to equipment and software purchase options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Preventice Solutions company profile →
Precardia
HQ: United States
Website
- Description: Provider of inpatient, partially implantable devices for treating patients with acute decompensated heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precardia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tissium
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tissium
2.2 - Growth funds investing in similar companies to Tissium
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tissium
4.2 - Public trading comparable groups for Tissium
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →